David Busse
8PUBLICATIONS
13CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Mar 10, 2025
Exposure-tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection.Ida Neldemo, Kamunkhwala Gausi, Céline Sarr
|Dec 10, 2024
A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.Robin Michelet, Klas Petersson, Marc C Huisman
|May 23, 2022
High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.D Busse, P Simon, D Petroff
|Dec 11, 2021
Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.David Busse, Philipp Simon, Lisa Schmitt
|Oct 23, 2021
Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients.David Busse, Jens Markus Borghardt, David Petroff
|Sep 28, 2021
Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics.David Busse, Philipp Simon, David Petroff
Pageof 2
Frequent Collaborators
5 joint publications
Philipp Simon
4 joint publications
Robin Michelet
4 joint publications
David Petroff
3 joint publications
Christoph Dorn
2 joint publications
Wilhelm Huisinga
1 joint publications
M Zeitlinger
1 joint publications
Frieder Kees
1 joint publications
Jens Markus Borghardt
1 joint publications
Hermann Wrigge
1 joint publications
Iris H C Miedema
